Development and Biological Evaluation of Novel Anticancer Drugs

Dear colleagues,

The anticancer effects of repurposed drugs and well-established non-oncologic drugs are an emerging field in the investigation of novel anticancer drugs. Sarcoma models are of fundamental importance in cancer treatment research due to the multiple pathological and clinical entities, resistance to current therapies, and high mortality attributed to these malignancies. Despite treatment protocols that combine chemotherapy, including methotrexate, cisplatin, doxorubicin, and ifosfamide, surgery, and radiotherapy, the 5-year survival rate for patients diagnosed with sarcoma is still not very high. Current treatment strategies for sarcomas, including fibrosarcoma, are associated with significant side effects, and there have been no significant improvements in prognosis in recent decades. Therefore, there is a need for improved, repurposed, and novel nontoxic therapies for the treatment of sarcoma and fibrosarcoma, as well as other types of cancer. This Special Issue will be devoted to investigations of novel and repurposed drugs that have significant new results in cancer treatment. We are interested in papers that provide examples of novel and repurposed uses of drugs that are new compared to well-established protocols in cancer treatment. This field of interest can include interactions of different drugs, reviews and meta-analyses, original research, and the use of software to determine desirable candidate molecules and drugs for repurposing.

Dr. Kosta Popović
Dr. Dušica Popović
Dr. Jovan K. Popović
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.